A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants After 10 Days of Oral Dosing
- Sponsor
- Novo Nordisk A/S
- Study ID
- NCT06820476
- Phase
- PHASE1
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- MALE
- Age
- 18 Years - 55 Years
- Healthy Volunteers
- Not accepted
Interventions
- NNC0487-0111 — DRUGParticipants will be randomized to receive NNC0487-0111 tablet orally at dose levels 1, 2, or 3.
- Placebo (NNC0487-0111) — DRUGParticipants will be randomized to receive a placebo tablet orally matched to NNC0487-0111.
Study Details
The study is testing a new study medicine called NNC0487-0111 for weight control in Chinese people with Body mass index (BMI) greater than or equal to (\>=) 24 kilogram per square meter (kg/m\^2). The aim of this study is to find out how safe the study medicine is and how it behaves in your body. Participants will either get NNC0487-0111 or placebo. Which treatment participants will get is decided by chance. Oral NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. The study will last for about 60 days.
Key Dates
- Start date
- Feb 9, 2025
- Status verified
- Aug 2025
- Primary completion
- May 14, 2025
- Completion
- May 14, 2025
Study Design
- Enrollment
- 29 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: NNC0487-0111 (dose 1)Participants will be randomized to receive a single dose of NNC0487-0111.
- Experimental: NNC0487-0111 (dose 2)Participants will be randomized to receive a single dose of NNC0487-0111.
- Experimental: NNC0487-0111 (dose 3)Participants will be randomized to receive a single dose of NNC0487-0111.
- Placebo Comparator: PlaceboParticipants will be randomized to receive matching Placebo to NNC0487-0111.
Primary Outcome Measure
Number of treatment emergent adverse events (TEAEs) [ Time Frame: From first NNC0487-0111 administration (Day 1) to completion of the end-of-study visit (Day 31) ]
Related Studies
- Diabetes and Heart Disease Risk in BlacksRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Physical and Behavioral Traits of Overweight and Obese AdultsRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss TreatmentPHASE2 · Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Phoenix, Arizona
- Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular SystemRecruiting · National Heart, Lung, and Blood Institute (NHLBI) · Washington D.C., District of Columbia